SEPN
SepternaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
SEP-631's Phase 1 profile and planned CSU Phase 2b trial provide the clearest near-term value inflection. SEP-479 adds a second clinical data path, while the reported cash runway supports execution.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.8.
What can break
Clinical-stage biotechnology valuation remains highly sensitive to program readouts and regulatory outcomes.
Momentum
78
Value
58
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.00 · Bull $60.00 · Bear $24.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $45.00
Why
Momentum78 · Δ7d -0.6
Value58 · Δ7d -0.0
Sentiment74 · Δ7d +9.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
78
26% active weight
Current posture
7d trendImproving
Δ7d
-0.6
Δ21d
-2.3
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.0
Sentiment
74
34% active weight
Current posture
7d trendImproving
Δ7d
+9.8
Δ21d
+8.2
Why this grade
Composite grade A. Momentum 78.5 / Value 57.5 / Sentiment 73.7
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.54B
Beta
-
Shares Out
45.08M
P/E (TTM) · Derived
-31.0
P/S (TTM)
-
P/FCF (TTM) · Derived
14.79
Rev YoY
+12011.0%
EPS YoY
-60.5%
Gross Margin
+97.8%
Op Margin
-
Net Debt
-$367.46M
Current Ratio
4.71
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology